lisofylline   Click here for help

GtoPdb Ligand ID: 9225

Synonyms: (R)-lisophylline | CT-1501R
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Lisophylline is an active metabolite of pentoxifylline. The compound has novel anti-inflammatory properties, likely through inhibition of IL-12 signalling and STAT-4 activation [2]. It is reported to prevent type 1 diabetes in preclinical models [3] and improve the function and viability of isolated or transplanted pancreatic islets [1]. Evidence suggests that combined treatment with lisofylline (for its anti-inflammatory action) and exendin-4 (to enhance beta-cell proliferation) can reverse autoimmune diabetes in the non-obese diabetic (NOD) mouse model [4].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 82.05
Molecular weight 280.15
XLogP 2.31
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC(CCCCn1c(=O)c2n(C)cnc2n(c1=O)C)O
Isomeric SMILES C[C@H](CCCCn1c(=O)c2n(C)cnc2n(c1=O)C)O
InChI InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 1/2 clinical trial in patients with type I diabetes mellitus (NCT01603121) was terminated as it was unable to enroll sufficient numbers of subjects.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01603121 Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus Phase 1/Phase 2 Interventional Eastern Virginia Medical School